Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985;28(4):425-8.
doi: 10.1007/BF00544361.

Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives

Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives

D R Abernethy et al. Eur J Clin Pharmacol. 1985.

Abstract

The effect of chronic (greater than 3 months) administration of low-dose oestrogen-containing (less than 50 micrograms oestrogen) oral contraceptives (OCS) on the pharmacokinetics of caffeine has been examined in a treated females matched with 9 non-smoking, drug-free, healthy control females of similar age, weight and ethnic origin. Each subject received 162 mg caffeine base orally after an overnight fast. OCS subjects had a prolonged elimination half-life of caffeine, (mean 7.88 h vs 5.37 h in the controls). This was the result of marked impairment of the plasma clearance of caffeine (1.05 vs 1.75 ml/min/kg, respectively) with no change in apparent volume of distribution (0.685 in OCS vs 0.7501/kg in the control group). The absorption parameters determined were peak plasma caffeine concentration (3.99 vs 4.09 micrograms/ml) and time to peak concentration after drug administration (1.52 vs 0.79), which was moderately prolonged in OCS users. Thus, caffeine clearance, previously reported to be a specific marker of cytochrome P-448 activity in man, is decreased by chronic OCS use. This suggests that OCS may cause significant impairment of this enzyme activity as assessed in vivo. With chronic caffeine consumption, OCS users are predicted to have an increased steady-state plasma caffeine concentration as compared to non-OCS users.

PubMed Disclaimer

References

    1. Clin Pharmacol Ther. 1983 Jul;34(1):48-53 - PubMed
    1. J Pharmacol Exp Ther. 1982 Jan;220(1):120-6 - PubMed
    1. Mol Pharmacol. 1968 Jan;4(1):10-4 - PubMed
    1. Clin Pharmacol Ther. 1981 Jan;29(1):106-10 - PubMed
    1. Clin Pharmacol Ther. 1983 May;33(5):591-602 - PubMed

Publication types

LinkOut - more resources